
Disparities in lung cancer biomarker testing show barriers that delay diagnosis and treatment for lower-income patients, according to Sandip P. Patel, MD.
Disparities in lung cancer biomarker testing show barriers that delay diagnosis and treatment for lower-income patients, according to Sandip P. Patel, MD.
The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.
The panel shares clinical practices for overcoming immunotherapy resistance in patients with non-small cell lung cancer.
A panel of experts on non-small cell lung cancer outline factors that impact how well patients respond to immunotherapy.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.